NLRP3 and liver dysplastic nodule: UC-MSC-derived miR-342-3p was shown to inhibit the activation of NLRP3 inflammasome through targeting the 3′-UTR of Caspase1 in renal tubular epithelial cells, which provides a beneficial strategy for UC-MSC administration on DN.